BETA


2021/0432(COD) Derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI CANFIN Pascal (icon: Renew Renew) CLUNE Deirdre (icon: EPP EPP), ENGERER Cyrus (icon: S&D S&D), EICKHOUT Bas (icon: Verts/ALE Verts/ALE), VILLANUEVA RUIZ Idoia (icon: GUE/NGL GUE/NGL)
Lead committee dossier:
Legal Basis:
RoP 163, TFEU 114, TFEU 168-p4

Events

2022/04/20
   Final act published in Official Journal
2022/04/12
   CSL - Draft final act
Documents
2022/04/12
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2022/04/12
   CSL - Final act signed
2022/04/07
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted by 555 votes to 0, with 3 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) No 536/2014 as regards a derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta.

Parliament adopted its position at first reading under the ordinary legislative procedure by taking over the Commission proposal.

This Regulation is closely linked to the Directive aimed at ensuring the long-term continuity of supply of medicinal products to Northern Ireland from the United Kingdom and at addressing the remaining supply problems in Cyprus, Ireland and Malta. It aims to ensure the supply of investigational medicinal products to these same markets.

The amendment to Regulation (EU) No 536/2014 aims to provide for derogations for medicinal products distributed in Northern Ireland, Cyprus, Ireland and Malta which are used as investigational medicinal products in clinical trials in these countries.

Specifically, the amending regulation provides that the importation of investigational medicinal products from other parts of the United Kingdom into Northern Ireland and, until 31 December 2024, into Cyprus, Ireland and Malta is not subject to the holding of a manufacturing and import authorisation, provided that the following conditions are met:

- the investigational medicinal products have undergone certification of batch release either in the Union or in parts of the United Kingdom other than Northern Ireland to verify compliance with the requirements set out in Regulation (EU) No 536/2014;

- the investigational medicinal products are only made available to clinical trial participants in the Member State into which the investigational medicinal products are imported or, if imported into Northern Ireland, are only made available to clinical trial participants in Northern Ireland.

The Regulation will enter into force on the day of its publication in the Official Journal of the European Union. It should apply from 31 January 2022.

Documents
2022/03/28
   EP - Decision by committee, without report
2022/02/23
   ESC - Economic and Social Committee: opinion, report
Documents
2022/02/02
   EP - CANFIN Pascal (Renew) appointed as rapporteur in ENVI
2022/01/20
   EP - Committee referral announced in Parliament, 1st reading
2021/12/17
   EC - Legislative proposal
Details

PURPOSE: to ensure the continuity of supply of investigational medicinal products to Northern Ireland, as well as to Cyprus, Ireland and Malta.

PROPOSED ACT: Regulation of the European Parliament and of the Council.

ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

BACKGROUND: Regulation (EU) No 536/2014 of the European Parliament and of the Council lays down the rules for investigational medicinal products intended to be used in clinical trials in the Union. According to the Regulation, read in conjunction with the Ireland/Northern Ireland Protocol to the UK Withdrawal Agreement, the importation of investigational medicinal products from third countries into the Union or Northern Ireland is subject to the holding of a manufacturing and import authorisation.

Cyprus, Ireland, Malta and Northern Ireland have always relied on the supply of medicines, including investigational medicines, from or through parts of the UK other than Northern Ireland.

On 25 January 2021, the Commission issued a notice on the application of the EU pharmaceutical acquis in markets historically dependent on the supply of medicines from or via Great Britain (i.e. Cyprus, Ireland, Malta and Northern Ireland) after the end of the transitional period. This notice provides for a one-year grace period (until the end of December 2021), including for import requirements for investigational medicinal products, in order to ensure an uninterrupted supply of medicines to Northern Ireland, Cyprus, Ireland and Malta.

Despite the transition period, it is still proving very difficult for some operators currently based in parts of the UK other than Northern Ireland to adapt as required by the Protocol. An interruption in the supply of investigational medicinal products would present a potential risk to the safety and well-being of participants in ongoing clinical trials and would hamper the establishment of new clinical trials in these Member States and Northern Ireland.

CONTENT: the proposal to amend Regulation (EU) No 536/2014 aims to provide for exemptions for medicinal products distributed in Northern Ireland, Cyprus, Ireland and Malta that are used as investigational medicinal products in clinical trials in those countries.

Specifically, the proposal provides that the importation of investigational medicinal products from other parts of the United Kingdom into Northern Ireland and, until 31 December 2024, into Cyprus, Ireland and Malta is not subject to the holding of a manufacturing and import authorisation , provided that the following conditions are met:

- the investigational medicinal products have undergone certification of batch release either in the Union or in parts of the United Kingdom other than Northern Ireland to verify compliance with the requirements set out in Article 63(1);

- the investigational medicinal products are only made available to clinical trial participants in the Member State into which the investigational medicinal products are imported or, if imported into Northern Ireland, are only made available to clinical trial participants in Northern Ireland.

This proposal should be read in conjunction with the proposal to amend Directives 2001/20/EC and 2001/83/EC in order to introduce exemptions from certain obligations relating to medicinal products for human use available in the United Kingdom in respect of Northern Ireland, as well as Cyprus, Ireland and Malta.

Documents

  • Draft final act: 00007/2022/LEX
  • Decision by Parliament, 1st reading: T9-0117/2022
  • Economic and Social Committee: opinion, report: CES0378/2022
  • Legislative proposal: EUR-Lex
  • Legislative proposal: COM(2021)0998
  • Legislative proposal: EUR-Lex COM(2021)0998
  • Economic and Social Committee: opinion, report: CES0378/2022
  • Draft final act: 00007/2022/LEX

History

(these mark the time of scraping, not the official date of the change)

docs/1
date
2022-02-23T00:00:00
docs
title: CES0378/2022
type
Economic and Social Committee: opinion, report
body
ESC
docs/2
date
2022-04-12T00:00:00
docs
title: 00007/2022/LEX
type
Draft final act
body
CSL
events/3
date
2022-04-12T00:00:00
type
Act adopted by Council after Parliament's 1st reading
body
EP/CSL
events/5
date
2022-04-20T00:00:00
type
Final act published in Official Journal
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Procedure completed
docs/1
date
2022-04-07T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2022-0117_EN.html title: T9-0117/2022
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/2/summary
  • The European Parliament adopted by 555 votes to 0, with 3 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) No 536/2014 as regards a derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta.
  • Parliament adopted its position at first reading under the ordinary legislative procedure by taking over the Commission proposal.
  • This Regulation is closely linked to the Directive aimed at ensuring the long-term continuity of supply of medicinal products to Northern Ireland from the United Kingdom and at addressing the remaining supply problems in Cyprus, Ireland and Malta. It aims to ensure the supply of investigational medicinal products to these same markets.
  • The amendment to Regulation (EU) No 536/2014 aims to provide for derogations for medicinal products distributed in Northern Ireland, Cyprus, Ireland and Malta which are used as investigational medicinal products in clinical trials in these countries.
  • Specifically, the amending regulation provides that the importation of investigational medicinal products from other parts of the United Kingdom into Northern Ireland and, until 31 December 2024, into Cyprus, Ireland and Malta is not subject to the holding of a manufacturing and import authorisation, provided that the following conditions are met:
  • - the investigational medicinal products have undergone certification of batch release either in the Union or in parts of the United Kingdom other than Northern Ireland to verify compliance with the requirements set out in Regulation (EU) No 536/2014;
  • - the investigational medicinal products are only made available to clinical trial participants in the Member State into which the investigational medicinal products are imported or, if imported into Northern Ireland, are only made available to clinical trial participants in Northern Ireland.
  • The Regulation will enter into force on the day of its publication in the Official Journal of the European Union. It should apply from 31 January 2022.
events/3
date
2022-04-12T00:00:00
type
Final act signed
body
CSL
docs/1
date
2022-04-07T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2022-0117_EN.html title: T9-0117/2022
type
Text adopted by Parliament, 1st reading/single reading
body
EP
events/2
date
2022-04-07T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2022-0117_EN.html title: T9-0117/2022
forecasts
  • date: 2022-04-05T00:00:00 title: Vote in plenary scheduled
procedure/stage_reached
Old
Awaiting Parliament's position in 1st reading
New
Awaiting Council's 1st reading position
events/1
date
2022-03-28T00:00:00
type
Decision by committee, without report
body
EP
procedure/legal_basis/0
Rules of Procedure EP 163
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's position in 1st reading
forecasts/0
date
2022-04-05T00:00:00
title
Vote in plenary scheduled
forecasts/0
date
2022-04-04T00:00:00
title
Indicative plenary sitting date
forecasts
  • date: 2022-04-04T00:00:00 title: Indicative plenary sitting date
forecasts
  • date: 2022-03-23T00:00:00 title: Indicative plenary sitting date
forecasts/0/date
Old
2022-03-07T00:00:00
New
2022-03-23T00:00:00
forecasts
  • date: 2022-03-07T00:00:00 title: Indicative plenary sitting date
committees/0
type
Responsible Committee
body
EP
committee_full
Environment, Public Health and Food Safety
committee
ENVI
associated
False
rapporteur
name: CANFIN Pascal date: 2022-02-02T00:00:00 group: Renew Europe group abbr: Renew
shadows
committees/0
type
Responsible Committee
body
EP
committee_full
Environment, Public Health and Food Safety
committee
ENVI
associated
False
events
  • date: 2022-01-20T00:00:00 type: Committee referral announced in Parliament, 1st reading body: EP
procedure/dossier_of_the_committee
  • ENVI/9/08019
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting committee decision
commission
  • body: EC dg: Health and Food Safety commissioner: KYRIAKIDES Stella
docs/0/summary
  • PURPOSE: to ensure the continuity of supply of investigational medicinal products to Northern Ireland, as well as to Cyprus, Ireland and Malta.
  • PROPOSED ACT: Regulation of the European Parliament and of the Council.
  • ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.
  • BACKGROUND: Regulation (EU) No 536/2014 of the European Parliament and of the Council lays down the rules for investigational medicinal products intended to be used in clinical trials in the Union. According to the Regulation, read in conjunction with the Ireland/Northern Ireland Protocol to the UK Withdrawal Agreement, the importation of investigational medicinal products from third countries into the Union or Northern Ireland is subject to the holding of a manufacturing and import authorisation.
  • Cyprus, Ireland, Malta and Northern Ireland have always relied on the supply of medicines, including investigational medicines, from or through parts of the UK other than Northern Ireland.
  • On 25 January 2021, the Commission issued a notice on the application of the EU pharmaceutical acquis in markets historically dependent on the supply of medicines from or via Great Britain (i.e. Cyprus, Ireland, Malta and Northern Ireland) after the end of the transitional period. This notice provides for a one-year grace period (until the end of December 2021), including for import requirements for investigational medicinal products, in order to ensure an uninterrupted supply of medicines to Northern Ireland, Cyprus, Ireland and Malta.
  • Despite the transition period, it is still proving very difficult for some operators currently based in parts of the UK other than Northern Ireland to adapt as required by the Protocol. An interruption in the supply of investigational medicinal products would present a potential risk to the safety and well-being of participants in ongoing clinical trials and would hamper the establishment of new clinical trials in these Member States and Northern Ireland.
  • CONTENT: the proposal to amend Regulation (EU) No 536/2014 aims to provide for exemptions for medicinal products distributed in Northern Ireland, Cyprus, Ireland and Malta that are used as investigational medicinal products in clinical trials in those countries.
  • Specifically, the proposal provides that the importation of investigational medicinal products from other parts of the United Kingdom into Northern Ireland and, until 31 December 2024, into Cyprus, Ireland and Malta is not subject to the holding of a manufacturing and import authorisation , provided that the following conditions are met:
  • - the investigational medicinal products have undergone certification of batch release either in the Union or in parts of the United Kingdom other than Northern Ireland to verify compliance with the requirements set out in Article 63(1);
  • - the investigational medicinal products are only made available to clinical trial participants in the Member State into which the investigational medicinal products are imported or, if imported into Northern Ireland, are only made available to clinical trial participants in Northern Ireland.
  • This proposal should be read in conjunction with the proposal to amend Directives 2001/20/EC and 2001/83/EC in order to introduce exemptions from certain obligations relating to medicinal products for human use available in the United Kingdom in respect of Northern Ireland, as well as Cyprus, Ireland and Malta.
forecasts
  • date: 2022-02-14T00:00:00 title: Indicative plenary sitting date
forecasts
  • date: 2022-02-14T00:00:00 title: Indicative plenary sitting date
committees/1
type
Committee Opinion
body
EP
committee_full
Industry, Research and Energy
committee
ITRE
associated
False
committees/2
type
Committee Opinion
body
EP
committee_full
Internal Market and Consumer Protection
committee
IMCO
associated
False
committees/3
type
Committee Opinion
body
EP
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
associated
False
docs/0/docs/0
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2021&nu_doc=0998
title
EUR-Lex